High materiality8/10
Sutro Biopharma initiated with a Buy at Stifel
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Sutro Biopharma was initiated with a Buy rating by Stifel Nicolaus, with a target price of $48. The current share price is about $24.15, suggesting substantial upside potential.
- Stifel buys Sutro Biopharma with a $48 target; price ~24.15.
Key facts
- 01
Target: $48
- 02
Posted price: $24.15
- 03
Analyst firm: Stifel Nicolaus
- 04
Analyst: Laura Prendergast
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.